CD55 regulates self-renewal and cisplatin resistance in endometrioidtumors Effective targeting of cancer stem cells (CSCs) requires neutralization of self-renewal and chemoresistance, but these phenotypes are often regulated by distinct molecular mechanisms. Here we report the ability to target both of these phenotypes via CD55, an intrinsic cell surface complement inhibitor, which pathways in endometrioidtumors.
Comparable outcome between endometrioid and non-endometrioidtumors in patients with early-stage high-grade endometrial cancer. Approximately 25% of endometrial cancer patients present with high-grade tumors. Unlike the clearly defined work-up for non-endometrioid endometrial cancer, no consensus exists for surgical staging and adjuvant therapy in high-grade endometrioid endometrial cancer. We different between early-stage high-grade endometrioid versus non-endometrioid endometrial cancer (P = 0.72). Distant recurrence and DRM was high in patients with endometrial cancer regardless of histological type, suggesting the need for different therapies in early-stage high-grade non-endometrioid and endometrioidtumors.
in contrast with the 30% survival rate for invasive tumors (all stages).Endometrioid TumorThe less common endometrioidtumor of low malignant potential should not be regarded as malignant because it seldom, if ever, metastasizes. Malignant transformation can, however, occur and may be associated with a similar tumor outside of the ovary; such tumors are the result of either a second primary or rupture Clin Oncol 19 (10): 2658-64, 2001. [PUBMED Abstract]Norris HJ: Proliferative endometrioidtumors and endometrioidtumors of low malignant potential of the ovary. Int J Gynecol Pathol 12 (2): 134-40, 1993. [PUBMED Abstract]Stage Information for Ovarian Low Malignant Potential TumorsIn This SectionThe Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) StagingThe Fédération Internationale
endometrioidtumors (grade 3), and characteristically arise from an atrophic endometrium. They demonstrate a worse prognosis and are responsible for almost half of the EC-related deaths [3]. Secondary to estimated errors in clinical staging resulting in the under staging of 13% to 22% of patients with EC, the International Federation of Gynecology and Obstetrics (FIGO) staging system has
pathogenic variants of *POLE* are identified in the gene’s exonuclease domain.25 26 This surrogate marker approach to the molecular-based classification has been demonstrated to be prognostically informative in low-, intermediate-, and high-risk endometrial carcinoma. Smaller studies showed that the molecular classification is also applicable to non-endometrioidtumors including serous, clear cell
), followed by cohort (20.7%, 95% CI: 20.1%, 21.3%) and period (14.2%, 95% CI: 13.7%, 14.8%) effects. Hexamaps showed higher incidence in recent years for non-Hispanic Blacks and non-endometrioidtumors. Age effects had the largest contribution to uterine cancer incidence, followed by cohort and period effects overall and across racial and ethnic groups and histologies. These findings can inform uterine
93.6% vs 92.1%, adjusted hazard ratio 0.87, 95% CI, 0.57-1.35). This survival association was consistent in high-grade serous (5-year rates 92.9% vs 92.4%), low-grade serous (100% vs 92.2%), clear cell (97.5% vs 86.1%), mucinous (92.1% vs 86.6%), low-grade endometrioid (95.7% vs 97.7%), and mixed (93.3% vs 83.7%) histology (all P>.05). In high-grade endometrioidtumor, fertility-sparing surgery -grade endometrioidtumors.
of endometrioidtumor, and 9 cases of mixed types. There were 41 cases of unilateral ovarian involvement, 38 cases of bilateral ovarian involvement. There were 5 cases of microinvasion, 17 cases of micropapillary subtype. Extra-ovarian invasive implants were found in 5 cases, and there were 31 cases of merged ascites. (2) Tumor outcomes: the median follow-up time from primary cytoreduction were 58 months (range
longer survival. In clear cell endometrial cancer, the presence of a definite admixed endometrioid or serous component did not correlate with a significant difference in prognosis. Patients whose tumors had indeterminate clear cell features had better prognosis. Some of these tumors may be endometrioidtumors mimicking clear cell carcinoma.
and hysterectomy. The prevalences of endometriosis and leiomyomas were 6.4% and 43.2% among Black participants and 7.0% and 21.5% among White participants, respectively. Endometriosis was associated with an increased risk of endometrioid and clear-cell ovarian cancer in both racial groups (eg, OR for endometrioidtumors for Black and White participants 7.06 [95% CI 3.86-12.91] and 2.17 [95% CI 1.36-3.45
EC patients. A total of 707 retrospective clinical early-stage EC patients were enrolled and randomly divided into a training cohort and a test cohort. Radiomics features were extracted from MR imaging. Three models were built, including a guideline-recommended clinical model (grade 1-2 endometrioidtumors by dilatation and curettage and less than 50% myometrial invasion on MRI without cervical
serous carcinoma, mixed germ cell tumor and mature teratoma, and a borderline ovarian endometrioidtumor exhibiting mesonephric differentiation. Four of the cases exhibited a KRAS variant and 3 also a PIK3CA variant. In reporting these cases, we expand on the published tumor types associated with MLA and report for the first time a borderline tumor exhibiting mesonephric differentiation. We show
surgery, endometrioid histology, well-differentiated tumors, T1a disease, and smaller tumor size were independently associated with sentinel lymph node biopsy use (P<.05). Performance of sentinel lymph node biopsy was not associated with increased endometrial cancer-specific mortality compared with lymphadenectomy for endometrioidtumors (subdistribution hazard ratio [HR] 0.96, 95% CI 0.82-1.13
was less common (17% vs 48%) (p < 0.01). Differences in gene mutations between cohorts corresponded to observed histologic differences between races. Specifically, TP53 mutations were predominant in serous tumors. In endometrioidtumors, mutations in ARID1A were the most common, and high rates of MSI-H, MMRd, and TMB-H were observed. In carcinosarcoma tumors, hormone receptor expression was high
endometrioidtumors and/or tumors with deep myometrial invasion were enrolled in this retrospective, multicentric study. After removal of SLNs, all patients underwent pelvic ± paraaortic lymphadenectomy. Operations were performed via laparotomy, laparoscopy or robotic surgery. Indocyanine green (ICG) and methylene blue (MB) were used as tracers. SLN detection rate, sensitivity, negative predictive value (NPV
women were identified. Minimally invasive IDS was performed in 31.1% and increased from 16.2% in 2010 to 40.4% in 2017 (P < 0.001). More recent year of diagnosis and performance of surgery at a comprehensive cancer center were associated with increased use of MIS (P < 0.05). Women with serous and clear cell tumors, and carcinosarcomas (compared to endometrioidtumors), as well as Medicaid coverage
A large multicenter propensity match study of sentinel lymph node biopsy feasibility in endometrioid variants of endometrial cancer. Sentinel lymph node (SLN) biopsy algorithm has been routinely applied in all endometrial endometrioidtumors, however, no studies analyzed the feasibility of SLN mapping in endometrioid variants (EV), which included villoglandular, secretory, ciliated cell
-ed in a study of 1895 women with stage III ovarian cancer treated withprimary cytoreduction and chemotherapy[13]. Independent predictorsof mortality were older age, worse Gynecologic Oncology Group (GOG)performance status, residual disease, and histology (compared with se-rous tumors, mortality was lower with endometrioidtumors and higherwith clear cell and mucinous tumors).5.2.2.2. Clinical
followed by external beam radiotherapy (RT), chemotherapy (CT), or a combination of CT + RT. Survival rates were calculated using the Kaplan-Meier method. The 5-year disease-specific survival (DSS) rate for all patients was 65%. Adjuvant CT + RT conferred higher rates of 5-year DSS as compared to CT alone in patients with grade 3 endometrioid and non-endometrioidtumors (61% vs. 27%, P = 0.04 and 67% vs . 38%, P = 0.02, respectively). Among patients with non-endometrioidtumors, treatment with concurrent chemoradiotherapy followed by additional sequential chemotherapy had higher 5-year DSS rates than with concurrent chemoradiotherapy alone (74% vs. 50%, P = 0.02). The 3-year pelvic recurrence rate was 5% with RT ± CT and 35% with CT alone (P < 0.001) for all patients. No paraaortic nodal failures